SCHEDULE: Woodline Partners Discloses 4.8% Stake in Sagimet Biosciences
Beneficial Ownership Disclosure
Woodline Partners LP has filed an amended Schedule 13G, reporting a 4.8% beneficial ownership stake in Sagimet Biosciences Inc.'s Series A Common Stock.
Summary
- Woodline Partners LP, an investment adviser, reported beneficial ownership of 1,501,357 shares of Sagimet Biosciences Inc.'s Series A Common Stock.
- This ownership represents 4.8% of the class, calculated based on 31,001,109 shares outstanding as of August 5, 2025.
- Woodline Partners LP holds sole voting power and sole dispositive power over all 1,501,357 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change or update to a previously reported ownership position.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Sagimet Biosciences Inc.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership, inherently neutral in sentiment regarding the issuer's performance or prospects.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- Woodline Partners LP certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing reflects a passive investment by an investment adviser in a biotechnology company. Such disclosures are routine for institutional investors holding significant, but non-controlling, stakes in public companies.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a passive investment approach.
Key Dates
| Date | Description |
|---|---|
| 2025-08-05 | Date as of which 31,001,109 shares of Series A Common Stock were reported outstanding in the Company's 10-Q. |
| 2025-09-30 | Date of event which requires filing of this statement (reporting period end). |
| 2025-11-14 | Date of filing of this Schedule 13G/A. |
Keywords
Sagimet Biosciences, Woodline Partners, Schedule 13G, Beneficial Ownership, Series A Common Stock, Investment Adviser, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.